# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Vaxart reported quarterly losses of 14 cents per share, inline with the analyst consensus estimate. Quarterly sales clocked in ...
These data will inform potential next steps, such as potentially conducting a Phase 2b study and potentially a GII.4 challenge ...
Vaxart (NASDAQ:VXRT) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. The company repo...
Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide protection to infants through...
Vaxart (NASDAQ:VXRT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 14....